All In MedTech

Device Trial Radar · NCT03400150

BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007

CLINICAL PROTOCOL for the INVESTIGATION Of the BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007

Last checked: Nov 19, 2026Latest source record: Feb 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingTitle says "pivotal". Randomized with 222 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

222

Actual

Start

Jan 3, 2018

Primary completion

Dec 10, 2021

Study completion Dec 10, 2021

Sponsor

Lead sponsor
BioProtectNot on our public-company list
Sponsor type
Industry
First posted
Jan 17, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Supportive care
FDA-regulated device
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The BioProtect Balloon Implant™ System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the balloon to reduce the radiation dose delivered to the anterior rectum. The balloon composed of a biodegradable material that maintains that space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time.

Conditions

  • Prostate Cancer

Interventions

  • balloonDevice

    balloon implantation

  • ControlOther

    Control - Marking \& IMRT are standard of care for prostate cancer - there is no study-specific intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Endpoint: Number of Subjects in the Balloon and Control Groups With Rectal, Device or Procedure-related Grade > 1 AEs Within 6 Months of ProcedureTime frame: Within 6 months from balloon implantation
  2. Efficacy Endpoint: Number of Subjects in the Balloon Group With Reduction of >25% in Rectal Volume Receiving 70 Gy (rV70)Time frame: 3 months

Locations

16 sites in 6 countries. Site status is shown where the registry gives one.

  • Western Radiation Oncology

    Apple Valley, California

  • KSK Medical Center

    Irvine, California

  • Advanced Urology Institute

    Daytona Beach, Florida

13 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.